Santhera Pharmaceuticals Holding AG

SANN

CH1276028821

Pharmaceuticals

Delayed Swiss Exchange Other stock markets 10:11:44 2024-04-23 am EDT			5-day change	1st Jan Change
9.51 ^CHF	-0.21%		+4.62%	-3.06%

Apr. 17	Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis	MT
Mar. 27	Santhera Pharmaceuticals Wins Priority Review for Duchenne Muscular Dystrophy Drug in China	MT

Santhera Completes Capital Increase for Financing Arrangements

September 23, 2021 at 01:01 am EDT

(MORE TO FOLLOW) Dow Jones Newswires

September 23, 2021 01:00 ET (05:00 GMT)

Latest news about Santhera Pharmaceuticals Holding AG

Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis	Apr. 17	MT
Santhera Pharmaceuticals Wins Priority Review for Duchenne Muscular Dystrophy Drug in China	Mar. 27	MT
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Grants Priority Review by China's NMPA	Mar. 27	CI
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical?s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology	Feb. 21	CI
Santhera's New Study Shows Efficacy, Safety Data for Duchenne Muscular Dystrophy Treatment	Feb. 14	MT
Santhera Pharmaceuticals Holding AG Launches AGAMREE in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy	Jan. 15	CI
Swiss Equities Get a Boost from UK’s Upside GDP Surprise	Jan. 12	MT
Santhera Pharmaceuticals Obtains UK Approval for Duchenne Muscular Dystrophy Treatment	Jan. 12	MT
Swiss Equities Edge Down After Central Banks Buzz	Dec. 18	MT
Santhera Pharmaceuticals Wins EU Nod for Duchenne Muscular Dystrophy Drug	Dec. 18	MT
Santhera Pharmaceuticals Names Chief Commercial, Technology Officers	Dec. 07	MT
Santhera Pharmaceuticals Holding Ag Promotes Promotion of Geert Jan Van Daal to Chief Commercial Officer and of Marc Schrader to Chief Technology Officer	Dec. 07	CI
Santhera Pharmaceuticals Receives U.S. FDA Approval of Agamree(R) for the Treatment of Duchenne Muscular Dystrophy	23-10-27	CI
Santhera, Catalyst Pharmaceuticals Secure US FDA Nod for Rare Neuromuscular Disease Drug	23-10-26	MT
Catalyst Pharmaceuticals Says Santhera's Agamree Gains FDA Approval for Duchenne Muscular Dystrophy Treatment	23-10-26	MT
Catalyst Pharmaceuticals to Commercialize Duchenne Treatment in 1Q24 After FDA Approval	23-10-26	DJ
US FDA approves Santhera's drug for rare muscular dystrophy	23-10-26	RE
US FDA approves Santhera's Duschenne drug	23-10-26	RE
Santhera Gets Positive Opinion From European Medicines Agency's Committee for Duchenne MD Drug	23-10-13	MT
Santhera Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of AGAMREE®? for the Treatment of Duchenne Muscular Dystrophy	23-10-13	CI
Transcript : Santhera Pharmaceuticals Holding AG, H1 2023 Earnings Call, Sep 07, 2023	23-09-07
Santhera Pharmaceuticals Narrows H1 Attributable Loss; Revenue Down	23-09-07	MT
Santhera Pharmaceuticals Holding AG Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-07	CI
Santhera Pharmaceuticals Closes Sale of Idebenone Business to Italy's Chiesi Farmaceutici	23-07-31	MT
Chiesi Farmaceutici S.p.A. acquired Raxone®/idebenone business worldwide from Santhera Pharmaceuticals Holding AG.	23-07-30	CI

Chart Santhera Pharmaceuticals Holding AG

Duration

Period

Chart Santhera Pharmaceuticals Holding AG

More charts

Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company operates through one business segment, which is the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The Company focuses also on development of gene therapy for the treatment of LAMA2 (Laminin Subunit Alpha 2) deficient congenital muscular dystrophy (CMD). Santhera operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.

Sector

Pharmaceuticals

Calendar

2024-04-25 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

9.53 CHF

Average target price

30 CHF

Spread / Average Target

+214.80%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
SANTHERA PHARMACEUTICALS HOLDING AG	-3.06%	96.31M
KYOWA KIRIN CO. LTD.	+12.05%	9.18B
SK BIOPHARMACEUTICALS CO., LTD.	-16.14%	4.78B
YUHAN CORPORATION	+4.07%	3.87B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+19.02%	3.73B
INDIVIOR PLC	+26.58%	2.52B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-26.55%	2.27B
BETTA PHARMACEUTICALS CO., LTD.	-25.70%	2.21B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+5.82%	1.95B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B

Specialty & Advanced Pharmaceuticals

Santhera Pharmaceuticals Holding AG

Equities

SANN

CH1276028821

Pharmaceuticals

Santhera Completes Capital Increase for Financing Arrangements

Latest news about Santhera Pharmaceuticals Holding AG

Chart Santhera Pharmaceuticals Holding AG

Company Profile

Income Statement Evolution

Analysts' Consensus

Quarterly revenue - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals